Comparison of the clinical efficacy of subcutaneous versus oral administration of methotrexate in patients with psoriasis vulgaris

Not Applicable

• Conditions: psoriasis vulgaris; psoriasis vulgaris, methotrexate, oral administration, subcutaneous injection

• Registration Number: TCTR20190705002
• Lead Sponsor: Faculty of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-07-05
• Study Completion: 2019-09-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Enrolling by invitation
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Entry criteria require a clinical diagnosis of psoriasis vulgaris in patients who had
the Psoriasis Area Severity Index (PASI) score > 10 or body surface area (BSA) involvement >10% or who had PASI score <10 or BSA < 10% but did not respond to topical treatment and being at least 18 years of age

Exclusion Criteria

Exclusion criteria include pregnant or lactating women, known hypersensitivity to methotrexate, patients with malignancy or HIV-infection or hepatitis B or C infection, tuberculosis, and abnormal liver or kidney or hematologic function. All patients will have a 12-week washout of any systemic therapies including systemic corticosteroid, methotrexate, cyclosporine, acitretin, other immunosuppressive drugs, biologics and phototherapy for psoriasis prior to receiving the study drugs

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical improvement at week 4, 8, 12, 16, 20, 24, amd 28 Psoriasis Area Severity Index (PASI) score

Secondary Outcome Measures

Name	Time	Method
patient's satisfaction at week 4, 8, 12, 16, 20, 24, amd 28 visual analog scale (VAS) method